Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine antimoniate versus meglumine antimoniate plus doxycycline for cutaneous leishmaniasis
TCTR20260831005Phase 1Recruiting
- Sponsor
- Combined Military Hospital Quetta
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of meglumine antimoniate and doxycycline in cutaneous leishmaniasis (CL) (2 arms), sponsored by Combined Military Hospital Quetta. Primary endpoint: Clinical cure rate at two months. Started Aug 2026; status: recruiting.
02
Drugs
meglumine antimoniatedoxycycline
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on TCTR20260831005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260831005.